AstraZeneca Invests $2B in Summit Therapeutics to Advance Ivonescimab-ADC Combinations
AZN sits 15% above its 52-week low of $146.1.
Summary
AstraZeneca invested $2 billion in Summit Therapeutics for a ~12% stake and launched a clinical collaboration combining Summit's ivonescimab with AstraZeneca's ADC portfolio, starting with Sone-Ve in GI cancers. The investment was completed on October 5, 2026.
Updated with an SEC 6-K filing · What changed
Updates
· SEC 6-K — AstraZeneca completed its $2 billion equity investment in Summit Therapeutics on October 5, 2026.
Key Events · M&A and Partnerships · AZN
-
Updated · · SEC 6-K
$2B Equity Investment in Summit Completed
AstraZeneca purchased ~109 thousand preferred shares convertible into Summit common stock at a 1:1,000 ratio, giving it rights equivalent to ~12.0% of outstanding common stock (10.6% fully diluted). The $2 billion equity investment was completed on October 5, 2026.
-
Sone-Ve + Ivonescimab Clinical Collaboration
The companies will jointly fund and run trials combining Sone-Ve (CLDN18.2 ADC) with ivonescimab in GI cancers, with each retaining rights to its own medicine.
-
Broader ADC Combination MOU
An MOU outlines intent to launch a global development program pairing ivonescimab with AstraZeneca's broader cancer portfolio, including additional ADCs.
-
Ivonescimab Regulatory Status
Ivonescimab is approved in China for certain NSCLC patients, with a BLA under FDA review for EGFR-mutated NSCLC and Phase III trials ongoing across multiple tumor types.
Analysis · AZN · Life Sciences
AstraZeneca deployed $2 billion to take a ~12% stake in Summit Therapeutics, securing access to ivonescimab — a first-in-class PD-1/VEGF bispecific with a BLA under FDA review in EGFR-mutated NSCLC. The deal pairs ivonescimab with AstraZeneca's ADC portfolio, starting with Sone-Ve in GI cancers, where AstraZeneca just reported positive Phase III overall survival data. The equity investment was completed on October 5, 2026. This is a major strategic bet on combination oncology and gives AstraZeneca a direct equity position in a key emerging competitor's asset.
How filings like this one have moved
In the 30 days to Oct 5, 2026, 36.9% of the 964 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.65%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, AZN was trading at $168.29 on NYSE in the Life Sciences sector, with a market capitalization of approximately $257.7B. The 52-week trading range was $146.10 to $212.71. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.